Comprehensive Study Guide on Nitric Oxide Donors and Inhibitors

The Role of the Endothelium and Endothelium-Derived Relaxing Factor

The endothelium consists of a thin layer of endothelial cells lining the interior surfaces of blood vessels and lymphatic vessels, acting as an interface between circulating blood or lymph in the lumen and the vessel wall. Cells in direct contact with blood are vascular endothelial cells, while those in contact with lymph are lymphatic endothelial cells. Anatomically, the endothelium resides in the tunica intima, while the tunica media contains smooth muscle and elastic tissue, and the tunica adventitia holds connective tissue. A healthy endothelium maintains vascular health through various mechanisms: dilatation, growth inhibition, antithrombotic activity, anti-inflammatory responses, and antioxidant effects. This healthy state is dominated by nitric oxide ($NO$), endothelium-derived hyperpolarising factor, and prostacyclin. Conversely, in disease states, the endothelium promotes constriction, growth, prothrombotic activity, proinflammatory responses, and pro-oxidant effects, dominated by Endothelin-1, Angiotensin II ($AII$), and the Angiotensin-converting enzyme ($ACE$) found on endothelial cell membranes.

In 1980, Furchgott and Zawadzki described the endothelium-dependent relaxation of blood vessels by acetylcholine ($ACh$). Subsequent studies in 1984 identified that factors like bradykinin, histamine, and $5$-hydroxytryptamine stimulate the release of endothelium-derived relaxing factor ($EDRF$), which modulates vessel tone. In 1987, Furchgott proposed that $EDRF$ was nitric oxide ($NO$). By 1989, nitric oxide synthase ($NOS$), the enzyme responsible for $NO$ production, was discovered and the pathway proposed. Production is influenced by neuronal and humoral mediators including adrenaline, noradrenaline, $ATP$, Adenosine, Substance P, Arginine Vasopressin ($AT/VP$), Thrombin, $Ca^{2+}$, Insulin, Angiotensin, $TNF-\alpha$, and $IL-6$. Regulatory molecules like arginase, asymmetric dimethylarginine ($ADMA$), and dimethylarginine dimethylaminohydrolase ($DDAH$) also affect the pathway.

Biochemistry and Biosynthesis of Nitric Oxide

Nitric oxide is a chemical compound with the formula $NO$ or the free radical gas designation $[NO^{\bullet}]$. At low concentrations, it regulates the circulatory and central nervous systems, while at high concentrations, it serves as a defense against infectious organisms and cancer cells. Unlike most neurotransmitters and hormones, $NO$ is not regulated by storage, release, or targeted degradation; it is used immediately after synthesis and does not require a receptor for its action. The synthesis of $NO$ requires a $Ca^{2+}$-calmodulin complex.

Nitric oxide is synthesized from L-arginine by nitric oxide synthase ($NOS$) isoenzymes, which are dimers found in neurons, skeletal muscles, endothelial cells, and immune cells. There are three primary isoforms, each encoded by separate genes: Neuronal $NOS$ ($nNOS$ or $NOS-1$), Macrophage or Inducible $NOS$ ($iNOS$ or $NOS-2$), and Endothelial $NOS$ ($eNOS$ or $NOS-3$). Structurally similar to cytochrome $P450$ enzymes, each isoform contains prosthetic groups including iron protoporphyrin IX (heme), flavin adenine dinucleotide ($FAD$), flavin mononucleotide ($FMN$), and tetrahydrobiopterin ($H_4B$). They bind L-arginine, reduced $NADPH$, and the calcium-calmodulin complex. The $Ca^{2+}$-calmodulin complex regulates electron transfer within the molecule; its binding activates $eNOS$ and $nNOS$, whereas $iNOS$ activation is calcium-independent and induced by stimuli.

Physiological Effects and Signaling Mechanisms

Nitric oxide serves as a powerful vasodilator across all vascular beds and a relaxant for smooth muscle tissues, such as erectile tissue. This relaxation occurs when $NO$ activates guanylyl cyclase, leading to the synthesis of cyclic guanosine monophosphate ($cGMP$). The $cGMP$ facilitates the dephosphorylation and inactivation of myosin light chains via the activation of myosin light chain phosphatase. Increased intracellular $cGMP$ levels also inhibit $Ca^{2+}$ entry and activate $K^+$ channels, leading to hyperpolarization. Pathophysiologically, $NO$ contributes to hypotension in septic shock. Beyond smooth muscle, $NO$ reduces platelet aggregation and neutrophil adhesion by reducing the expression of adhesion molecules like integrins. In inflammation, tissue injury triggers $NO$ synthesis, which facilitates inflammatory responses directly and through the stimulation of prostaglandin synthesis via cyclooxygenase $2$ ($COX-2$). In the lungs, excessive concentrations of inhaled $NO$ or nitrites can convert hemoglobin to methemoglobin, potentially causing hypoxia.

Nitric oxide mediates its effects through covalent protein modifications targeting metalloproteins, thiols, and tyrosine. As a target of metalloproteins, $NO$ binds to the heme iron in soluble guanylyl cyclase ($sGC$) to generate $cGMP$, which then activates protein kinase G ($PKG$). It also inhibits enzymes with iron-sulfur clusters like aconitase, mitochondrial respiration via cytochrome oxidase inhibition, and heme-containing cytochrome $P450$ enzymes. Interaction with thiols ($-SH$ groups) results in S-nitrosylation, which can activate or inhibit protein function (e.g., activating H-ras or inhibiting glyceraldehyde-$3$-phosphate dehydrogenase). This process is reversible by intracellular reducing agents. Glutathione can interact with $NO$ to form S-nitrosoglutathione, a stable carrier of $NO$. Furthermore, $NO$ reacts with superoxide to form peroxynitrite ($ONOO^-$), a potent oxidant causing DNA damage and irreversible tyrosine nitration. Increased peroxynitrite is linked to cellular degeneration in ischemia and apoptotic mechanisms.

Related Nitrogen Oxides and Their Functions

Various nitrogen species exhibit distinct biological functions. Nitric oxide ($NO$) acts as a vasodilator, platelet inhibitor, immune regulator, and neurotransmitter. Peroxynitrite ($NO_3^-$) acts as an oxidant and nitrating agent. Nitroxyl anion ($NO^-$) exhibits action similar to $NO$ by oxidizing like $NO$. Nitrous oxide ($N_2O$) is utilized as an anesthetic. Dinitrogen trioxide ($N_2O_3$) is an auto-oxidation product of $NO$ capable of nitrosylating protein bonds. Nitrite ($NO_2^-$) decomposes to $NO$ at acidic $pH$, while Nitrate ($NO_3^-$) is a stable oxidation product of $NO$.

Nitric Oxide Synthesis Inhibitors

The primary strategy for reducing $NO$ generation involves $NOS$ inhibitors, most of which are L-arginine analogs that bind to the arginine binding site. Generally, these are nonselective. Key inhibitors include $N^{\omega}$-Monomethyl-L-arginine (L-NMMA) and $N^{\omega}$-Nitro-L-arginine methyl ester (L-NAME), both of which are competitive nonselective inhibitors. $7$-Nitroindazole is a competitive inhibitor binding to both tetrahydrobiopterin and arginine sites, showing partial selectivity for $NOS-1$ in vivo. S-Methylthiocitrulline inhibits $iNOS$ dimerization while weakly inhibiting $nNOS$ and $eNOS$. Hemoglobin acts as an $NO$ scavenger. Therapeutic targets for inhibition include neurodegenerative diseases (via $nNOS$), hemostatic signaling (via $eNOS$), and inflammatory disorders (via $iNOS$).

Nitric Oxide Donors: Organic Nitrates

Nitric oxide donors release $NO$ directly or undergo bioactivation. The principal organic nitrates are Nitroglycerin (glyceryl trinitrate or $GTN$), Isosorbide dinitrate ($ISDN$), and Isosorbide mononitrate ($ISMN$). Nitroglycerin requires enzymatic bioactivation by mitochondrial aldehyde dehydrogenase-$2$ ($ALDH2$). At therapeutic doses, these drugs predominantly dilate veins, increasing venous capacitance and decreasing venous return (preload) to reduce myocardial $O_2$ demand. Higher doses dilate arterioles to reduce systemic vascular resistance (afterload). They also dilate large epicardial coronary arteries to relieve vasospasm. The main benefit in angina is reduced demand rather than increased coronary flow.

Nitroglycerin is used for rapid relief of acute angina (sublingual tablet or spray), short-term prevention, and acute pulmonary edema or heart failure (intravenous infusion). Sublingual administration avoids first-pass metabolism, acting within minutes. Adverse effects include throbbing headaches (from cranial vessel dilation), flushing, dizziness, postural hypotension, syncope, and reflex tachycardia. Nitrate tolerance occurs with continuous exposure, requiring a daily nitrate-free interval of $10$-$12$ hours. Tolerance mechanisms include impaired bioactivation and oxidative stress. Nitroglycerin is critically contraindicated with phosphodiesterase inhibitors like Sildenafil, Tadalafil, Vardenafil, Avanafil, and Riociguat due to the risk of fatal hypotension.

Isosorbide mononitrate is a long-acting nitrate for angina prevention, unsuitable for acute attacks due to slow onset. It has nearly complete oral bioavailability, minimal first-pass metabolism, and a half-life of $4$-$6$ hours. It is the principal active metabolite of Isosorbide dinitrate. Isosorbide dinitrate is used for angina prevention and heart failure (in combination with hydralazine). It undergoes substantial first-pass metabolism and produces active metabolites (Isosorbide-$5$-mononitrate and Isosorbide-$2$-mononitrate). In heart failure, $ISDN$ reduces preload while hydralazine reduces afterload.

Alternate Donors and Enhancement Strategies

Organic Nitrites, such as Isoamylnitrite, are volatile antianginals requiring metabolic activation. They are arterial dilators and do not exhibit the same rapid tolerance as nitrates. Sodium Nitroprusside is used for rapid blood pressure reduction in arterial hypertension, generating $NO$ in response to light or chemical/enzymatic mechanisms. Hybrid $NO$ donors involve adding $NO$-donating moieties to existing drugs, such as $SNOCap$, which adds a nitrosothiol to Captopril. Therapeutic $NO$ gas inhalation is used to reduce pulmonary artery pressure and improve perfusion in acute respiratory distress syndrome, acute hypoxemia, and cardiopulmonary resuscitation. Another strategy to enhance $NO$ activity is through Phosphodiesterase type $5$ ($PDE-5$) inhibition. Drugs like Sildenafil inhibit the breakdown of $cGMP$, prolonging $NO$-induced signaling.

Nitric Oxide in Clinical Conditions and Disease States

Nitric oxide impacts various systems. In the vascular system, it causes vasodilatation; vasodilators like $ACh$ and bradykinin induce $NO$ synthesis. Inhibition of $NOS$ increases the effects of vasopressor drugs. $NO$ is antithrombotic and anti-atherogenic by inhibiting vascular smooth muscle proliferation and platelet aggregation. It reduces the expression of adhesion molecules, preventing monocyte and leukocyte adhesion. It may act as an antioxidant, preventing the oxidation of low-density lipoproteins and foam cell formation. Risk factors like smoking, hyperlipidemia, and diabetes decrease endothelial $NO$ production, enhancing atherogenesis.

In septic shock, lipopolysaccharides from gram-negative bacteria induce $iNOS$, causing exaggerated hypotension. While inhibitors like L-NMMA can reverse this, nonselective inhibitors haven't clearly improved survival rates. In inflammation, cytokines like $TNF$ and $IL-1$ induce $iNOS$ in leukocytes and fibroblasts; while $NO$ is a microbicide, overproduction can exacerbate tissue injury. In the central nervous system, $NO$ acts as a neuromodulator. It is induced at postsynaptic sites via $NMDA$ receptors, acting as a retrograde messenger to enhance neurotransmitter release. It facilitates long-term potentiation (memory). Excessive $NO$ and glutamate are implicated in neurodegenerative diseases like Alzheimer's and Parkinson's. In Parkinson's, glial cells produce neurotoxic levels of $NO$, contributing to dopaminergic neuronal loss. In the peripheral nervous system, $NO$ is a mediator for non-adrenergic, non-cholinergic ($NANC$) neurons, notably facilitating penile erection.

Questions & Discussion

Which one of the following is not a nitric oxide donor but causes it to be released from endogenous precursors, resulting in vasodilation?
Acetylcholine is the correct answer. Nitroprusside, organic nitrites (e.g., amyl nitrite), and nitrates (e.g., Nitroglycerin, isosorbide dinitrate, and isosorbide mononitrate) contain $NO$ groups that can be directly released. Acetylcholine stimulates the production of $NO$ from its natural source, L-arginine.

A molecule that releases nitric oxide in the blood is?
Nitroprusside is the molecule identified that releases $NO$ in the bloodstream.

The inducible isoform of nitric oxide synthase (iNOS, isoform 2) is found primarily in which of the following?
Macrophages contain the highest concentration of $iNOS$, as this form is associated with inflammation.

The primary endogenous substrate for the enzyme nitric oxide synthase (NOS) is?
Arginine is the substrate, while citrulline and $NO$ are the products of the reaction.

Which of the following is a recognized effect of nitric oxide (NO)?
Pulmonary vasodilation is a recognized effect. $NO$ does not cause arrhythmias, constipation, or bronchoconstriction; it causes bronchodilation.

Which of the following is an approved application for nitric oxide administered as a gas?
Pulmonary hypertension is an approved application. Inhaled $NO$ gas is also approved for neonatal hypoxic respiratory failure.